ELECTRONIC PRESCRIBING SYSTEMS INTEGRATION WITH GENOMICS

Detailed Explanation with Case Laws

1. INTRODUCTION

Electronic Prescribing Systems Integration With Genomics refers to the integration of electronic prescription software with genomic and pharmacogenomic information to improve the safety, accuracy, and effectiveness of medical treatment.

Electronic prescribing enables doctors to prescribe medicines digitally, while pharmacogenomics examines how genetic variations influence an individual's response to medicines. By combining these technologies, healthcare professionals can identify potential drug-related risks, select suitable medicines, and determine appropriate dosages.

For example, genetic variations in the CYP2C19 gene can influence a patient's response to clopidogrel. An integrated prescribing system may alert the doctor to consider an alternative medicine when clinically appropriate.

This integration raises important legal issues concerning patient privacy, informed consent, medical negligence, data protection, cybersecurity, and professional accountability.

2. MEANING AND DEFINITION

Electronic Prescribing: A digital system used by healthcare professionals to create, transmit, and manage prescriptions.

Genomics: The study of an individual's complete genetic material and its functions.

Pharmacogenomics: The study of how genetic variations affect the response of an individual to medicines.

Clinical Decision Support System: Software that analyses clinical information and provides alerts or recommendations to assist healthcare professionals in making treatment decisions.

Therefore, genomics-integrated electronic prescribing is a technology-assisted healthcare system that combines medication information and relevant genetic results to support personalised medical treatment.

3. OBJECTIVES

The principal objectives are:

To promote personalised medicine.

To reduce the risk of adverse drug reactions.

To support appropriate dosage selection.

To improve medication safety.

To identify clinically significant gene–drug interactions.

To improve communication between doctors, laboratories, and pharmacists.

To maintain accurate electronic medical records.

To support evidence-based treatment decisions.

4. WORKING MECHANISM

The system generally operates through the following stages:

First: The patient undergoes an appropriate genetic test.

Second: The laboratory verifies and reports the relevant genetic findings.

Third: The findings are incorporated into the patient's electronic health record.

Fourth: The doctor enters a proposed medicine into the electronic prescribing system.

Fifth: The clinical decision support software checks for relevant gene–drug interactions.

Sixth: The system generates an alert if the genetic information indicates a potential risk or the need to consider an alternative medicine or dosage.

Seventh: The doctor evaluates the recommendation in light of the patient's clinical condition and other medicines.

Eighth: The prescription and the reasons for accepting or overriding an alert are documented.

The software supports professional judgment; it does not replace the doctor's responsibility to assess the patient's condition.

5. LEGAL FRAMEWORK

A. Right to Privacy

Genomic information is sensitive because it may reveal details about an individual's health and biological relationships. Healthcare organisations must protect such information from unauthorised access and disclosure.

In India, the constitutional right to privacy recognised in Justice K.S. Puttaswamy v. Union of India (2017) provides an important foundation for protecting medical information.

B. Informed Consent

Patients should receive understandable information about the purpose of genetic testing, its limitations, and the intended use of their results. Additional consent or another lawful basis may be required for research or unrelated secondary uses, depending on the circumstances and applicable law.

C. Medical Negligence

A doctor who disregards a reliable and clinically significant genetic warning without reasonable justification may face scrutiny for professional negligence. However, an adverse outcome or a computer-generated alert alone does not automatically establish negligence.

D. Data Protection

Healthcare providers should implement appropriate security measures, including access controls, encryption, audit logs, and secure information-sharing procedures.

The Digital Personal Data Protection Act, 2023, and its implementing framework must be considered according to the commencement status of the relevant provisions and the circumstances of the processing.

E. Professional Accountability

Doctors, hospitals, laboratories, and software providers may have different responsibilities. Liability depends on the applicable law, contractual obligations, professional standards, and the conduct that contributed to the harm.

6. IMPORTANT CASE LAWS

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Court: Supreme Court of India.

Principle: The Supreme Court recognised privacy as a fundamental right under Article 21 and the broader constitutional framework.

Relevance: Genetic information must be handled with appropriate respect for privacy and confidentiality. Unnecessary disclosure of genomic information may interfere with an individual's privacy rights.

Legal Significance: The judgment provides a constitutional foundation for protecting sensitive personal and medical information.

2. Samira Kohli v. Dr. Prabha Manchanda (2008)

Court: Supreme Court of India.

Principle: The Court explained the requirements of valid informed consent in medical treatment.

Relevance: Patients should understand the purpose and scope of genetic testing and the proposed clinical use of their results. Consent for one procedure should not automatically be treated as unrestricted consent for materially different interventions.

Legal Significance: The case reinforces patient autonomy and informed decision-making.

3. Jacob Mathew v. State of Punjab (2005)

Court: Supreme Court of India.

Principle: The Court discussed medical negligence and the distinction between an unfortunate medical outcome and legally actionable negligence.

Relevance: A doctor's failure to consider a clinically significant pharmacogenomic warning may be examined when determining whether the applicable standard of care was breached.

Legal Significance: The decision provides guidance on evaluating professional responsibility in medical treatment.

4. Montgomery v. Lanarkshire Health Board (2015)

Court: UK Supreme Court.

Principle: The Court held that doctors must take reasonable care to ensure that patients are informed of material risks and reasonable alternative treatments.

Relevance: If genetic information identifies a material risk associated with a proposed medicine, the doctor should communicate that risk and discuss reasonable alternatives where appropriate.

Legal Significance: The judgment supports informed patient choice in personalised medicine.

5. Moore v. Regents of the University of California (1990)

Court: Supreme Court of California, United States.

Principle: The Court rejected the patient's conversion claim concerning the commercial use of his excised cells but recognised the importance of disclosure of relevant physician research and financial interests.

Relevance: The case raises issues concerning biological materials, genetic research, commercial interests, and transparency in healthcare.

Legal Significance: It illustrates the importance of disclosure and informed consent in medical research. It does not establish a general property right in all genetic information.

6. Canterbury v. Spence (1972)

Court: United States Court of Appeals for the District of Columbia Circuit.

Principle: The judgment is a leading authority on the disclosure of material risks in medical treatment.

Relevance: In genomics-integrated prescribing, relevant risks and reasonable treatment alternatives should be explained to patients in accordance with the applicable legal standard.

Legal Significance: The case provides comparative guidance on informed consent and patient autonomy.

Note: These cases establish related principles concerning privacy, consent, and medical negligence. They should not be described as direct judicial decisions specifically regulating genomics-integrated electronic prescribing.

7. MAJOR LEGAL CHALLENGES

1. Genetic Privacy: Unauthorised disclosure may expose sensitive health information.

2. Inaccurate Data: Incorrect genetic results or faulty data integration may generate unsafe prescribing recommendations.

3. Algorithmic Bias: Systems trained on insufficiently representative populations may produce less reliable recommendations for some patients.

4. Alert Fatigue: Excessive warnings may cause doctors to overlook clinically important alerts.

5. Unclear Liability: Disputes may arise concerning the responsibility of doctors, laboratories, hospitals, and software developers.

6. Informed Consent: Patients may not fully understand how their genetic data will be stored, shared, or reused.

7. Cybersecurity Risks: Hacking, unauthorised access, and data breaches may compromise confidential medical records.

8. Unequal Access: The cost of genetic testing and advanced prescribing systems may create disparities in healthcare.

8. MEASURES FOR EFFECTIVE IMPLEMENTATION

The following measures can improve the safety and legal compliance of genomics-integrated prescribing:

Verify the accuracy and clinical validity of genetic test results.

Use scientifically validated pharmacogenomic guidelines.

Obtain appropriate consent and explain relevant data uses.

Restrict genomic data access to authorised personnel.

Maintain secure records of prescriptions and clinical alerts.

Train doctors and pharmacists to interpret genetic information.

Conduct regular cybersecurity assessments.

Update clinical decision support systems as scientific evidence develops.

Establish clear procedures for reviewing and overriding alerts.

Define accountability among healthcare institutions, laboratories, and software suppliers.

9. CONCLUSION

Electronic Prescribing Systems Integration With Genomics is an important development in personalised medicine. It combines digital prescription management with genetic information to support safer medication selection, appropriate dosage decisions, and the prevention of avoidable adverse drug reactions.

However, technological progress must be balanced with privacy, informed consent, data security, professional accountability, and equitable access to healthcare.

The principles established in Puttaswamy, Samira Kohli, Jacob Mathew, Montgomery, Moore, and Canterbury provide useful legal guidance for analysing these issues, although they do not all directly concern electronic prescribing integrated with genomics.

Ultimately, effective implementation requires scientifically validated technology, meaningful patient consent, strong data protection, and responsible clinical decision-making.